Who Paid My Doc
Karla Menjivar
Nurse Practitioner, Family Los Angeles, CA Nurse Practitioner
NPI 1205155447 CMS profile 10993589
1700 Cesar Chavez Ave, Suite 3900, Los Angeles, CA 90033
General payments
$36,458
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Karla Menjivar of Los Angeles, CA is reported in the CMS Open Payments database as having received $36,458 across 662 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $11,829 | 147 | |
| 2024 | General | $14,415 | 207 | |
| 2023 | General | $6,559 | 132 | |
| 2022 | General | $2,755 | 122 | |
| 2021 | General | $901 | 54 |
Beside peers
- Karla Menjivar
- Nurse Practitioner, Family median
- Middle half of Nurse Practitioner, Family
- National median
In program year 2025, general payments to Karla Menjivar were reported at $11,829. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.
Show as a table
| Year | Karla Menjivar | Nurse Practitioner, Family median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $39 | $18–$91 | $163 |
| 2020 | $0 | $32 | $17–$76 | $114 |
| 2021 | $901 | $124 | $35–$379 | $132 |
| 2022 | $2,755 | $141 | $44–$430 | $149 |
| 2023 | $6,559 | $154 | $49–$476 | $160 |
| 2024 | $14,415 | $165 | $51–$504 | $164 |
| 2025 | $11,829 | $168 | $53–$521 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 66 drugsPart D claims
4,878
Drug cost
$2,221,209
Branded share of claims
65.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Kerendia Finerenone | Brand | 669 | $423,533 | |
| Farxiga Dapagliflozin Propanediol | Brand | 374 | $228,429 | |
| Rybelsus Semaglutide | Brand | 218 | $209,080 | |
| Lokelma Sodium Zirconium Cyclosilicate | Brand | 214 | $180,286 | |
| Auryxia Ferric Citrate | Brand | 118 | $152,944 | |
| Repatha Sureclick Evolocumab | Brand | 267 | $140,360 | |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | Brand | 166 | $137,630 | |
| Jardiance Empagliflozin | Brand | 196 | $119,601 | |
| Veltassa Patiromer Calcium Sorbitex | Brand | 92 | $87,141 | |
| Ozempic Semaglutide | Brand | 75 | $70,693 |
The 10 drugs with the highest cost, of 66 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 30 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| KRYSTEXXA |
|
$9,587 | — | — |
| Kerendia |
|
$332 | 669 | — |
| FARXIGA |
|
$316 | 374 | — |
| ACTHAR |
|
$274 | — | — |
| PURIFIED CORTROPHIN GEL |
|
$255 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 30 with PatronRecords
662 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Family in California
Lori Robertson
Nurse Practitioner, Family · Chino Hills, CA
Annette Shon
Nurse Practitioner, Family · Los Angeles, CA
Lisa Higgins
Nurse Practitioner, Family · Hanford, CA
Jennifer Tougas
Nurse Practitioner, Family · Bakersfield, CA
Kim Schafer
Nurse Practitioner, Family · Sacramento, CA
Dawn Meyer
Nurse Practitioner, Family · San Diego, CA
Related records
Nurse Practitioner, Family in California
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Family
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.